GU CONNECT has summarised the highlights of the recent ASCO GU 2019 meeting for you.
Prostate cancer update by Prof. Evan Y. Yu, University of Washington School of Medicine, Fred Hutchinson Cancer Research Center, Seattle, USA.
GU CONNECT has summarised the highlights of the recent ASCO GU 2019 meeting for you.
Prostate cancer update by Prof. Evan Y. Yu, University of Washington School of Medicine, Fred Hutchinson Cancer Research Center, Seattle, USA.
Dr. Evan Y. Yu is a medical oncologist specializing in genitourinary malignancies, specifically prostate, bladder and testicular cancer treatment and research. His research focuses on testing the next wave of novel molecular targeted therapies and immunotherapy techniques, with a complementary focus on imaging biomarkers. He is Section Head, Medical Oncology in the Clinical Research Division at Fred Hutch Cancer Center. He also serves as the Medical Director for Clinical Research for the Fred Hutch/University of Washington/Seattle Children’s Cancer Consortium. He is a Professor at the University of Washington and Fred Hutch Cancer Center. He is principal investigator for the National Cancer Trials Network Lead Academic Performance Site (LAPS) Grant, SWOG, and ECOG/ACRIN. Dr. Yu is also the core director for the Pacific Northwest Prostate Cancer SPORE and co-PI of the DoD Prostate Cancer Clinical Trials Consortium for his institution. He graduated Alpha Omega Alpha from the University of Washington School of Medicine. Previously, he served as a Hematology/Oncology Fellowship Program Director for a decade at Fred Hutch. He has regularly been voted a “Top Doctor” by Castle Connolly, Seattle Magazine, and Seattle Met magazine. He has served for many years on the National Cancer Institute Genitourinary Cancers Steering Committee and is currently the co-chair for the National Cancer Institute Prostate Cancer Task Force. Dr. Yu has held various leadership/committee roles within ASCO, AACR, and also serves as a senior editor for Clinical Cancer Research and Uro-Today.
Insights from patients and caregivers
Expert insights on how the latest evidence is shaping clinical practice
Using molecular testing to enable personalised care
Experts discuss 2nd line+ treatment strategies in endocrine therapy-eligible patients
Expert insights on the latest data
Understanding EP-NEC, emerging treatments, and patient care strategies